000516 Xi'An International Medical Investment
- 4.63
- -0.04-0.86%
Xi'An International Medical Investment News
Xi'an International Medical Investment (000516.SZ) has repurchased 0.4865% of its total shares.
Xi'an International Medical Investment (000516.SZ) announced that as of July 31, 2024, the company has repurchased 10,997,100 shares of company stock through the Shenzhen Stock Exchange trading system in a centralized bidding transaction, accounting for 0.4865% of the company's current total share capital. The highest fill price was 5.618 yuan/share and the lowest fill price was 4.61 yuan/share, with a total fill amount of 57,426,831.72 yuan (excluding transaction fees). The progress of the repurchase program complies with relevant laws and regulations and the established share repurchase program of the company.
Xi'An International Medical Investment: 2024 Interim Performance Forecast
Xi'an International Medical Investment (000516.SZ) has spent 57.43 million yuan to repurchase 10.9971 million shares.
Xi'an international medical investment (000516.SZ) announced that as of June 30, 2024, the company has cumulatively passed the Shenzhen...
Xi'an International Medical Center Hospital South and North Campus have an average daily bed occupancy rate of about 3500-3600.
On June 27th, Geelong reported that Xi'an International Medical Investment (000516.SZ) has performed well in recent business operations, with all medical institutions conducting orderly operations and an overall positive growth trend. The average daily hospital bed usage rate for both the north and south campuses of Xi'an International Medical Center is about 3,500-3,600 beds, while for Xi'an Gaoxin Hospital, the average daily hospital bed usage rate is about 1,500-1,600 beds. With increasing patient visits and bed usage rates in their medical institutions, the company is seeing a sustained growth trend in business performance and improved profitability.
International Medicine (000516.SZ): Initial repurchase of 2.3 million shares involving 128.56 million yuan
Gelonghui, May 27丨International Medicine (000516.SZ) announced that on May 27, 2024, for the first time, the company repurchased 2.3 million shares of the company's shares through a dedicated stock repurchase securities account, accounting for 0.1017% of the company's current total share capital. The highest transaction price was 5.62 yuan/share, the lowest transaction price was 5.54 yuan/share, and the total transaction amount was 128.56 million yuan (excluding transaction fees).
Gelonghui Fund Daily | The “magic foundation” strategy for small and micro capitalization stocks is quietly changing!
Focus on the latest fund information
International Medicine (000516.SZ): Affiliated medical institutions use chemotherapy, endocrine therapy, targeted treatment, etc. for common solid tumors
Gelonghui, May 17 | International Medicine (000516.SZ) said on the investor interactive platform that the company's medical institutions are characterized by chemotherapy, endocrine therapy, targeted therapy, immunotherapy, malignant tumor radiotherapy, thyroid breast surgery, and intravenous infusion port implantation for chemotherapy patients. Well-known cancer treatment centers and senior experts within the United Nations provide patients with scientific, standardized and individualized diagnosis and treatment plans.
International Medicine (000516.SZ): The main operating costs are medical business costs, including procurement costs of pharmaceuticals and consumables, personnel expenses, depreciation and amortization, etc.
Gelonghui, May 17 | International Medicine (000516.SZ) said on the investor interactive platform that the company's main operating costs are medical business costs, including procurement costs of pharmaceuticals and consumables, personnel expenses, depreciation and amortization, etc. In the future, the company will continuously optimize cost control, improve operational efficiency, and promote high-quality development of the company's main medical industry.
International Medicine (000516.SZ): The company's medical institutions have more than 500 items including cell morphology testing centers, immunological testing centers, cytogenetic testing centers, and preventive medicine
Gelonghui, May 17 | International Medicine (000516.SZ) said on the investor interactive platform that the company's medical institutions have cell morphology testing centers, immunological testing centers, cytogenetics testing centers, molecular biology testing centers, stem cell and immune cell transformation centers. The testing programs cover more than 500 items such as hematological diagnosis, treatment, prognostic assessment guidance, tumor diagnosis and targeted therapy, pharmacogenomics, and preventive medicine, to protect patients in multiple dimensions and angles.
International Medicine (000516.SZ): Net profit for the first quarter - $105 million
On April 25, Ge Longhui (000516.SZ) released its report for the first quarter of 2024, achieving operating income of 1,173 billion yuan, an increase of 10.75% over the previous year; net profit attributable to shareholders of listed companies - 105 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 898.496 million yuan, basic earnings per share - 0.0464 yuan.
International Medicine (000516.SZ): Chairman, Vice Chairman and all executives increased their holdings by a total of 537,900 shares
Gelonghui, Feb. 2 | International Medicine (000516.SZ) announced that the company received notifications from the chairman, vice chairman and all senior management of the company to learn that the company's chairman, Ms. Shi Jin, Vice Chairman, Ms. Wang Aiping, Director and President Mr. Liu Ruixuan, Director and Vice President, Mr. Sun Wenguo, Vice President and Board Secretary, Mr. Wang Yu, Vice President, Mr. Sun Yikuan, Vice President, and Ms. Wang Yaxing increased the company's shares by centralized bidding through the Shenzhen Stock Exchange trading system from January 31 to February 2, 2024, accounting for Total share capital of the company 2,260
International Medicine (000516.SZ) issued a forecast loss. The net loss for 2023 is expected to be 280 million yuan to 370 million yuan
International Medicine (000516.SZ) announced its 2023 annual results forecast, which is expected to be owned by shareholders of listed companies for the whole year...
International Medicine (000516.SZ): The company's three major comprehensive medical hospitals currently have 10,137 planned beds, and currently the number of beds in use exceeds 5,000
On December 29, Ge Longhui | International Medicine (000516.SZ) said on the investor interactive platform that after years of exploration, international medicine has developed an innovative “comprehensive medical+specialty” business model, fully relying on existing Level 3 A and international JCI certification. Miaoyou Medical Alliance member hospitals provide a full-life cycle medical and health service platform to provide high-quality comprehensive medical services to patients to meet diverse medical and health needs. The company's three comprehensive medical hospitals currently have 10,137 planned beds. Currently, the number of beds in use exceeds 5,000, according to the company's latest five-year development regulations
International Medicine (000516.SZ): In the third quarter, its medical institutions added 23 new hospitals cooperating with the Medical Federation
On November 16, Gelonghui International Medicine (000516.SZ) recently stated during a survey of institutional investors that in the third quarter of 2023, the company's medical institutions added 23 new hospitals cooperating with the medical consortium; the proportion of overseas patients in high-tech hospitals reached 31.31%; the proportion of overseas patients in central hospitals reached 37.93%, and the proportion of overseas patients in the company's medical institutions continued to grow.
International Medicine (000516.SZ): The proton therapy center is currently being built and is expected to be put into use in 2025
Gelonghui, November 16|International Medicine (000516.SZ) recently stated during a survey from institutional investors that construction of the proton therapy center is currently being accelerated. Due to its long construction period, it is expected to be put into use in 2025.
International Medicine (000516.SZ): Xi'an Gaoxin Hospital has the highest number of daily use of more than 1,700 beds
On November 16, Gelonghui International Medicine (000516.SZ) stated at an investor relations event that the number of inpatient services in the company's medical institutions is constantly increasing. Recently, the number of beds used on the highest day in the north-south campus of Xi'an International Medical Center Hospital reached more than 3,700, and the number of beds used on the highest day in Xi'an High-tech Hospital reached more than 1,700.
Changchun Hi-Tech (000661.SZ): The subsidiary won the 35B-02 plot of Shanghai International Medical Park in Pudong New Area for 162 million yuan
GLONGHUI, September 26丨Changchun Hi-Tech (000661.SZ) announced that Shanghai Saizeng Medical Technology Co., Ltd., a wholly-owned subsidiary of the company's holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), participated in the state-owned construction land use rights online listing and sale campaign organized by the Shanghai Pudong New Area Planning and Natural Resources Bureau on September 26, 2023. It won RMB 1619.8 million for state-owned construction land use land use rights for plot 35B-02 of the Shanghai International Medical Park in Pudong New Area, and obtained the “sale of state-owned construction land use rights” “Confirmation Form”, and completed
Interpretation of the International Medicine 2023 Interim Report: Operating income increased sharply, net profit loss decreased
According to the 2023 Interim Report of International Medicine, the company's revenue was 2,209,788,795.81 yuan, an increase of 106.91% compared to 1,068,020,568.30 yuan in the same period last year. This indicates that the company's business scale expanded significantly during the reporting period. However, net profit attributable to shareholders of listed companies was -222,259,756.80 yuan. Although it decreased by 62.69% compared to the loss of -595,727,097.49 yuan in the same period last year, it is still in a state of loss. At the same time, deductions attributable to shareholders of listed companies are not recurring
International Medicine (000516.SZ): Net loss of 222 million yuan in the first half of the year
GLONGHUI, August 23 | International Medicine (000516.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 2,209.8 billion yuan, up 106.91% year on year; net profit attributable to shareholders of listed companies was -222 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -255 million yuan; basic earnings per share were -0.0977 yuan.
Yixian E-commerce debuted at WCD International Medical Event with two major brands
In recent years, along with the iterative upgrading of beauty technology, the power of domestic beauty products has gradually attracted the attention of the international market. Yixian e-commerce, with the vision of “an explorer of health and beauty in the era of new technology”, has in-depth insight into the market and consumer needs, gathers medical research and research forces, and recently appeared on the stage of the International Conference of the World Congress of Dermatology. At the 25th World Congress of Dermatology (WCD) of the 25th World Congress of Dermatology (WCD) held in Singapore from July 3-8, Yixian E-commerce participated for the first time with its two major brands, Effective Skincare Dahl Skin Care and Premium Skincare, France's Clanley, participated in the acclaim
Analysis
Price Target
No Data
